Voyager Therapeutics, Inc. (VYGR)
NMS · Healthcare · Biotechnology
Closing price as of 2026-06-08 · Source: TEK2day Finance
Key Metrics
About Voyager Therapeutics, Inc.
Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of alzheimer's disease. The company also provides research program for the treatment of Huntington's disease. In addition, it offers TRACER, an adeno-associated virus (AAV) capsid discovery platform; ALPL-VYGR-NeuroShuttle, to target an undisclosed neurological disease; and develops selective small molecules for the treatment of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia with TDP-43 pathology. The company has collaboration and license agreements with Alexion; AstraZeneca Ireland Limited; Novartis Pharma AG; and Transition Bio, Inc. for the treatment of various other diseases of the central nervous system. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 5.2M | 13.4M | 15.3M | 2.6M |
| Operating Income | -36.6M | -30.6M | -29.9M | -30.3M |
| Net Income | -33.4M | -27.9M | -27.4M | -27.9M |
| Diluted EPS | $-0.57 | $-0.47 | $-0.47 | $-0.47 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 40.9M | 250.0M | 80.0M | 40.4M |
| Operating Income | -50.8M | 122.0M | -83.3M | -131.8M |
| Net Income | -46.4M | 132.3M | -65.0M | -119.7M |
| Diluted EPS | $-1.21 | $2.97 | $-1.13 | $nan |